Ertapenem sodium salt CAS:153773-82-1

Ertapenem sodium salt is indicated for the treatment of complicated intra-abdominal infections, complicated skin and soft tissue infections, community-acquired pneumonia, and complicated urinary tract infections. Its spectrum of activity covers both Gram-positive and Gram-negative bacteria, including multi-drug resistant pathogens like extended-spectrum beta-lactamase (ESBL)-producing bacteria. Healthcare providers may also utilize ertapenem sodium salt for postoperative surgical prophylaxis to prevent surgical site infections in high-risk patients undergoing certain procedures. The dosing regimen and duration of treatment are determined based on the type of infection, severity, and patient factors. Due to its once-daily dosing schedule and broad coverage against challenging pathogens, ertapenem sodium salt is a valuable option in hospital settings for serious infections requiring parenteral therapy. Close monitoring for signs of infection resolution, adverse reactions, and laboratory parameters is essential during treatment. Patients receiving ertapenem sodium salt should follow their healthcare provider's instructions regarding administration, infusion rate, and potential side effects. Common adverse effects include gastrointestinal disturbances, hypersensitivity reactions, and changes in laboratory test results such as liver enzymes. Overall, ertapenem sodium salt plays a critical role in treating complex bacterial infections and providing effective therapy against multidrug-resistant pathogens. When used judiciously and in accordance with prescribing guidelines, ertapenem sodium salt contributes to improved patient outcomes and helps combat challenging infectious diseases in clinical practice.